Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neurogenin-3 (NEUROG3) is a basic helix-loop-helix transcription factor essential for the development of endocrine lineages in the pancreas and intestine. NEUROG3 governs the specification and differentiation of pancreatic islet cells (including insulin-producing beta cells) and mature enteroendocrine cells of the intestine. Mutations cause congenital absence of enteroendocrine cells, leading to malabsorptive diarrhea and sometimes neonatal or early-onset diabetes. NEUROG3 acts mainly by binding to E-box sequences in target gene promoters—often as a heterodimer with E proteins like E47—regulating gene transcription involved in endocrine cell fate. Its expression and activity are tightly controlled at transcriptional and post-translational levels, with rapid turnover via the ubiquitin-proteasome system and regulation by phosphorylation and deubiquitination[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neurogenin-3 (NEUROG3).